Data released by the World Health Organization shows that about 17.5 million people died of cardiovascular diseases worldwide in 2012, accounting for 31% of all deaths worldwide. According to statistics, the number of patients with cardiovascular diseases in China was about 290 million in 2018, and the prevalence and mortality rate were still on the rise, accounting for more than 40% of the disease deaths of residents. Cardiovascular disease can be called the "No.1 Killer" of human beings. The heart failure caused by the treatment will also continue to affect the survival of patients.
On August 20, 2024, Du Jie, chief scientist of Beijing Institute of Cardiovascular and Vascular Diseases, and Beijing Sungen Biomedical jointly developed SGC001 injection for the treatment of acute myocardial infarction. A launching meeting of phase I clinical trial was held in the research ward of Anzheng Hospital. This means that once it passes phase 3 clinical trials, it will be the first emergency antibody developed to treat heart attacks. After the heart attack happens, a shot is all you need -- something millions of heart failure patients have never imagined.
In 2024, "innovative drugs", as one of the actively cultivated emerging industries, was written into the Government Work Report. On June 6, the "Key Tasks for Deepening the Reform of the Medical and Health System in 2024" issued by The General Office of the State Council also mentioned "innovative drugs" many times. According to statistics, in 2023, China has nearly 70 foreign licenses of innovative drugs, with a total transaction amount of more than $46.5 billion.
The world's first FIC innovative drug SGC001 injection jointly developed by Professor Du Jie's team and Professor Sun Zhiwei's team from Sungen Biomedical is a monoclonal antibody drug for the emergency treatment of patients with Acute Myocardial Infarction (AMI). Till now, there is no antibody therapy for AMI approved for clinical or commercial stage. Sungen Biomedical's SGC001 injection (Dukiprubart) has obtained IND approval in China and the United States. SGC001 has the potential to become a first-in-class drug, providing safer and more effective therapies for AMI patients worldwide.
AMI is a condition characterized by death of myocardia due to acute occlusion of coronary arteries, resulting in high morbidity, mortality, disability rates, as well as serious complications. According to professional epidemiological surveys in China, the mortality of AMI is 2.5 million people per year, and the incidence of AMI reaches millions of patients per year. There is a trend of younger onset of AMI. Findings from prospective PEACE study (Patient-centered Evaluative Assessment of Cardiac Events) published in 2020 suggested that, the number of AMI patients may reach 23 million by 2030 in China. AMI places a significant economic burden on the society and families. According to the Report on Cardiovascular Health and Diseases in China 2022, the total cost of hospitalization for cardiovascular and cerebrovascular diseases in China was 270.901 billion yuan in 2020, with 34.685 billion yuan for AMI. AMI is one of the most important public health problems.
Updated: Dec 17, 2024
